Search

Your search keyword '"Mai, Elias K"' showing total 163 results
Start Over Author "Mai, Elias K" Publication Year Range Last 3 years
163 results on '"Mai, Elias K"'

1. CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Author

Kriegsmann, Katharina, Ton, Gigi Nu Hoang Quy, Awwad, Mohamed H. S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Munder, Markus, Dürig, Jan, Blau, Igor W., Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja C., Salwender, Hans J., Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., and Hundemer, Michael

Published
2024
Full Text
View/download PDF

3. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Author

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, and Goldschmidt, Hartmut

Published
2024
Full Text
View/download PDF

5. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Author

Cirrincione, Anthony M., Poos, Alexandra M., Ziccheddu, Bachisio, Kaddoura, Marcella, Bärtsch, Marc-Andrea, Maclachlan, Kylee, Chojnacka, Monika, Diamond, Benjamin, John, Lukas, Reichert, Philipp, Huhn, Stefanie, Blaney, Patrick, Gagler, Dylan, Rippe, Karsten, Zhang, Yanming, Dogan, Ahmet, Lesokhin, Alexander M., Davies, Faith, Goldschmidt, Hartmut, Fenk, Roland, Weisel, Katja C., Mai, Elias K., Korde, Neha, Morgan, Gareth J., Usmani, Saad, Landgren, Ola, Raab, Marc S., Weinhold, Niels, and Maura, Francesco

Published
2024
Full Text
View/download PDF

8. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

Author

Adrian, Nicole, Bernhard, Helga, Böck, Hans-Peter, Bolling, Claus, Dingeldein, Gerrit, Emde, Till-Oliver, Ferstl, Barbara, Fietz, Thomas, Fronhoffs, Stefan, Fuhrmann, Stephan, Fuxius, Stefan, Geer, Thomas, Görner, Martin, Guenther, Barbara, Hartmann, Frank, Heilmeier, Bernhard, Heinsch, Michael, Hoffmann, Martin, Holderried, Tobias A.W., Klein, Stefan, Klump, Martin, Knauf, Wolfgang, La Rosée, Paul, Lange, Elisabeth, Lindemann, Walter, Lopez, Roderico, Mayer, Frank, Nückel, Holger, Papesch, Eva, Procaccianti, Maria, Reichart, Alexander, Rummel, Mathias, Scheuer, Lars, Schmitt, Hans-Roland, Staib, Peter, Steiniger, Heike, Tischler, Hans-Joachim, Ulshöfer, Thomas, Verbeek, Walter, Wacker, Alexander, Zirpel, Iris, Mai, Elias K, Goldschmidt, Hartmut, Miah, Kaya, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Krzykalla, Julia, Fenk, Roland, Schlenzka, Jana, Munder, Markus, Dürig, Jan, Blau, Igor W, Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Kunz, Christina, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M, Kunz, Christian, Hensel, Manfred, Benner, Axel, Seidel-Glätzer, Andrea, Weisel, Katja C, Raab, Marc S, and Salwender, Hans J

Published
2024
Full Text
View/download PDF

9. Reproducible Radiomics Features from Multi‐MRI‐Scanner Test–Retest‐Study: Influence on Performance and Generalizability of Models

Author

Wennmann, Markus, primary, Rotkopf, Lukas T., additional, Bauer, Fabian, additional, Hielscher, Thomas, additional, Kächele, Jessica, additional, Mai, Elias K., additional, Weinhold, Niels, additional, Raab, Marc‐Steffen, additional, Goldschmidt, Hartmut, additional, Weber, Tim F., additional, Schlemmer, Heinz‐Peter, additional, Delorme, Stefan, additional, Maier‐Hein, Klaus, additional, and Neher, Peter, additional

Published
2024
Full Text
View/download PDF

10. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Author

Asemissen, Anne M, Behringer, Joachim, Bernhard, Helga, Bernhardt, Christiane, Bertsch, Uta, Besemer, Britta, Blau, Igor W, Bolling, Claus, Debatin, Daniel, Dingeldein, Gerrit, Dürig, Jan, Fenk, Roland, Ferstl, Barbara, Fest, Claudia, Fronhoffs, Stefan, Fuhrmann, Stephan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Görner, Martin, Graeven, Ullrich, Grassinger, Jochen, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Held, Gerhard, Hoffmann, Martin, Holderried, Tobias A W, Hopfer, Olaf, Huhn, Stefanie, Immenschuh, Peter, Kaddu-Mulindwa, Dominic, Khandanpour, Cyrus, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Köchling, Georg, Koenigsmann, Michael, Kostrewa, Philippe, Kraemer, Doris Maria, Kremers, Stephan, Kriegsmann, Katharina, Kropff, Martin, La Rosée, Paul, Luntz, Steffen P, Mahlberg, Rolf, Mai, Elias K, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Müller, Martin, Munder, Markus, Neise, Michael, Nievergall, Eva, Nückel, Holger, Pönisch, Wolfram, Procaccianti, Maria, Raab, Marc S, Rafiyan, Mohammed R, Reimer, Peter, Riecke, Armin, Riesenberg, Hendrik, Rummel, Mathias, Runde, Volker, Salwender, Hans J, Schaich, Markus, Scheid, Christoph, Schmidt-Hieber, Martin, Schmitt, Stefan, Schöndube, Daniel, Schroers, Roland, Schwarzer, Andreas, Staib, Peter, Steiniger, Heike, Sturmberg, Dirk, Thomalla, Jörg, Tichy, Diana, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Trummer, Arne, Tschechne, Barbara, Verbeek, Walter, Weinhold, Niels, Weisel, Katja C, Whitlock, Bettina, de Wit, Maike, Zaiß, Matthias, Ziske, Carsten, and Scheid, Christof

Published
2022
Full Text
View/download PDF

11. Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.

Author

Zuern, Kosima, Hielscher, Thomas, Werly, Annika, Breitkreutz, Iris, Sauer, Sandra, Raab, Marc S., Müller-Tidow, Carsten, Goldschmidt, Hartmut, and Mai, Elias K.

Subjects
MONOCLONAL gammopathies, RISK assessment, MULTIPLE myeloma, PLASMA cell diseases
Abstract

Risk of progression of monoclonal gammopathy of undetermined significance (MGUS) into multiple myeloma and related plasma cell disorders can be determined by three major risk stratification models, namely Mayo2005, Sweden2014, and NCI2019. This retrospective study of 427 patients with MGUS diagnosed according to the 2014 International Myeloma Working Group criteria aimed to describe and analyze the longitudinal applicability of these risk models. In all three models, the majority of patients remained at their baseline risk group, whereas small numbers of patients migrated to a different risk group. Proportions of patients among risk groups remained stable over time (e.g. Mayo2005 model, low-risk group, at baseline: 43%, after 1, 2, 3, 4, 5, and 8 years: 40%, 37%, 37%, 43%, 44%, and 43%). All three risk models reliably distinguished risk of progression at baseline, upon yearly reassessment (e.g. 1 year from diagnosis) and in time-dependent analyses. Upstaging to a high-risk category was associated with an increased risk of progression in all three models (Mayo2005: hazard ratio [HR] = 5.43, 95% confidence interval [95% CI] 1.21–24.39, p = 0.027; Sweden2014: HR = 13.02, 95% CI 5.25–32.28, p < 0.001; NCI2019: HR = 5.85, 95% CI 2.49–13.74, p < 0.001). Our study shows that MGUS risk stratification models can be applied longitudinally to repeatedly determine and improve individual risk of progression. Patient migration to higher risk categories during follow up should prompt more frequent monitoring in clinical routine. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial

Author

Mai, Elias K, primary, Goldschmid, Hartmut, additional, Miah, Kaya, additional, Bertsch, Uta, additional, Besemer, Britta, additional, Hänel, Mathias, additional, Krzykalla, Julia, additional, Fenk, Roland, additional, Schlenzka, Jana, additional, Munder, Markus, additional, Dürig, Jan, additional, Blau, Igor W, additional, Huhn, Stefanie, additional, Hose, Dirk, additional, Jauch, Anna, additional, Kunz, Christina, additional, Mann, Christoph, additional, Weinhold, Niels, additional, Scheid, Christof, additional, Schroers, Roland, additional, von Metzler, Ivana, additional, Schieferdecker, Aneta, additional, Thomalla, Jörg, additional, Reimer, Peter, additional, Mahlberg, Rolf, additional, Graeven, Ullrich, additional, Kremers, Stephan, additional, Martens, Uwe M, additional, Kunz, Christian, additional, Hensel, Manfred, additional, Benner, Axel, additional, Seidel-Glätzer, Andrea, additional, Weisel, Katja C, additional, Raab, Marc S, additional, Salwender, Hans J, additional, Adrian, Nicole, additional, Bernhard, Helga, additional, Böck, Hans-Peter, additional, Bolling, Claus, additional, Dingeldein, Gerrit, additional, Emde, Till-Oliver, additional, Ferstl, Barbara, additional, Fietz, Thomas, additional, Fronhoffs, Stefan, additional, Fuhrmann, Stephan, additional, Fuxius, Stefan, additional, Geer, Thomas, additional, Görner, Martin, additional, Guenther, Barbara, additional, Hartmann, Frank, additional, Heilmeier, Bernhard, additional, Heinsch, Michael, additional, Hoffmann, Martin, additional, Holderried, Tobias A.W., additional, Klein, Stefan, additional, Klump, Martin, additional, Knauf, Wolfgang, additional, La Rosée, Paul, additional, Lange, Elisabeth, additional, Lindemann, Walter, additional, Lopez, Roderico, additional, Mayer, Frank, additional, Nückel, Holger, additional, Papesch, Eva, additional, Procaccianti, Maria, additional, Reichart, Alexander, additional, Rummel, Mathias, additional, Scheuer, Lars, additional, Schmitt, Hans-Roland, additional, Staib, Peter, additional, Steiniger, Heike, additional, Tischler, Hans-Joachim, additional, Ulshöfer, Thomas, additional, Verbeek, Walter, additional, Wacker, Alexander, additional, and Zirpel, Iris, additional

Published
2024
Full Text
View/download PDF

13. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Author

Salwender, Hans, Elmaagacli, Ahmet, Merz, Maximilian, Miah, Kaya, Benner, Axel, Haenel, Mathias, Jehn, Christian, Mai, Elias K., Bertsch, Uta, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Raab, Marc S., Luntz, Steffen P., Besemer, Britta, Munder, Markus, Brossart, Peter, Fuhrmann, Stephan, Lindemann, Hans-Walter, Weisel, Katja, Duerig, Jan, and Goldschmidt, Hartmut

Published
2021
Full Text
View/download PDF

14. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma:data from five randomized, controlled, phase III trials in 3700 patients

Author

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, Goldschmidt, Hartmut, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, and Goldschmidt, Hartmut

Abstract

Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the training cohort experienced severe infections, death, or both, respectively. Four major, baseline risk factors for severe infection/death were identified: low platelet count (<150/nL), ISS III, higher WHO performance status (>1), and age (>60 years). A risk score (1 risk factor=1 point) stratified patients in low (39.5%; 0 points), intermediate (41.9%; 1 point), and high (18.6%; ≥2 points) risk. The risk for severe infection/death increased from 7.7% vs. 11.5% vs. 23.3% in the low- vs. intermediate- vs. high-risk groups (p < 0.001). The risk score was independently validated in three trials incorporating quadruplet IT with an anti-CD38 antibody. Our analyses established a robust and easy-to-use score to identify NDMM patients at risk of severe infection/death, covering the latest quadruplet induction therapies. Trial registrations: HOVON-65/GMMG-HD4: EudraCT No. 2004-000944-26. GMMG-MM5: EudraCT No. 2010-019173-16. GMMG-HD6: NCT02495922. EMN02/HOVON-95: NCT01208766. GMMG-HD7: NCT03617731.

Published
2024

15. Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.

Author

Sachpekidis, Christos, Enqvist, Olof, Ulén, Johannes, Kopp-Schneider, Annette, Pan, Leyun, Mai, Elias K., Hajiyianni, Marina, Merz, Maximilian, Raab, Marc S., Jauch, Anna, Goldschmidt, Hartmut, Edenbrandt, Lars, and Dimitrakopoulou-Strauss, Antonia

Subjects
ARTIFICIAL intelligence, BONE marrow, MULTIPLE myeloma, IMAGE segmentation, PLASMA cells, RECEIVER operating characteristic curves, LIVER
Abstract

Purpose: Multiple myeloma (MM) is a highly heterogeneous disease with wide variations in patient outcome. [18F]FDG PET/CT can provide prognostic information in MM, but it is hampered by issues regarding standardization of scan interpretation. Our group has recently demonstrated the feasibility of automated, volumetric assessment of bone marrow (BM) metabolic activity on PET/CT using a novel artificial intelligence (AI)–based tool. Accordingly, the aim of the current study is to investigate the prognostic role of whole-body calculations of BM metabolism in patients with newly diagnosed MM using this AI tool. Materials and methods: Forty-four, previously untreated MM patients underwent whole-body [18F]FDG PET/CT. Automated PET/CT image segmentation and volumetric quantification of BM metabolism were based on an initial CT-based segmentation of the skeleton, its transfer to the standardized uptake value (SUV) PET images, subsequent application of different SUV thresholds, and refinement of the resulting regions using postprocessing. In the present analysis, ten different uptake thresholds (AI approaches), based on reference organs or absolute SUV values, were applied for definition of pathological tracer uptake and subsequent calculation of the whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Correlation analysis was performed between the automated PET values and histopathological results of the BM as well as patients' progression-free survival (PFS) and overall survival (OS). Receiver operating characteristic (ROC) curve analysis was used to investigate the discrimination performance of MTV and TLG for prediction of 2-year PFS. The prognostic performance of the new Italian Myeloma criteria for PET Use (IMPeTUs) was also investigated. Results: Median follow-up [95% CI] of the patient cohort was 110 months [105–123 months]. AI-based BM segmentation and calculation of MTV and TLG were feasible in all patients. A significant, positive, moderate correlation was observed between the automated quantitative whole-body PET/CT parameters, MTV and TLG, and BM plasma cell infiltration for all ten [18F]FDG uptake thresholds. With regard to PFS, univariable analysis for both MTV and TLG predicted patient outcome reasonably well for all AI approaches. Adjusting for cytogenetic abnormalities and BM plasma cell infiltration rate, multivariable analysis also showed prognostic significance for high MTV, which defined pathological [18F]FDG uptake in the BM via the liver. In terms of OS, univariable and multivariable analysis showed that whole-body MTV, again mainly using liver uptake as reference, was significantly associated with shorter survival. In line with these findings, ROC curve analysis showed that MTV and TLG, assessed using liver-based cut-offs, could predict 2-year PFS rates. The application of IMPeTUs showed that the number of focal hypermetabolic BM lesions and extramedullary disease had an adverse effect on PFS. Conclusions: The AI-based, whole-body calculations of BM metabolism via the parameters MTV and TLG not only correlate with the degree of BM plasma cell infiltration, but also predict patient survival in MM. In particular, the parameter MTV, using the liver uptake as reference for BM segmentation, provides solid prognostic information for disease progression. In addition to highlighting the prognostic significance of automated, global volumetric estimation of metabolic tumor burden, these data open up new perspectives towards solving the complex problem of interpreting PET scans in MM with a simple, fast, and robust method that is not affected by operator-dependent interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.

Author

Schreiner, Sarah, Berghaus, Natalie, Poos, Alexandra M., Raab, Marc S., Besemer, Britta, Fenk, Roland, Goldschmidt, Hartmut, Mai, Elias K., Müller-Tidow, Carsten, Weinhold, Niels, Hegenbart, Ute, Huhn, Stefanie, and Schönland, Stefan O.

Subjects
MULTIPLE myeloma, IMMUNOGLOBULIN light chains, AMYLOIDOSIS, RNA sequencing, MULTIPLE comparisons (Statistics)
Abstract

AL amyloidosis (AL) results from the misfolding of immunoglobulin light chains (IG LCs). Aim of this study was to comprehensively analyse kappa LC sequences from AL patients in comparison with multiple myeloma (MM). We analysed IGKV/IGKJ usage and associated organ tropism and IGKV1/D-33 in terms of mutational analysis and theoretical biochemical properties. cDNA and bulk RNA sequencing of the LCs of AL and MM patients. We studied 41 AL and 83 MM patients showing that IGKV1 was most expressed among kappa AL and MM, with higher frequency in AL (80% vs. 53%, p =.002). IGKV3 was underrepresented in AL (10% vs. 30%, p =.014). IGKJ2 was more commonly used in AL than in MM (39% vs. 29%). Patients with IGKV1/D-33 were associated with heart involvement (75%, p =.024). IGKV1/D-33-segments of AL had a higher mutation count (AL = 12.0 vs. MM = 10.0). FR3 and CDR3 were most frequently mutated in both, with a median mutation count in FR3 being the highest (AL = 4.0; MM = 3.5) and one mutation hotspot (FR3 (83I)) for IGKV1/D-33/IGKJ2 was associated with cardiac involvement. This study confirmed that germline usage has an influence on AL amyloidosis risk and organ involvement. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Genomic Classification and Individualized Prognosis in Multiple Myeloma

Author

Maura, Francesco, primary, Rajanna, Arjun Raj, additional, Ziccheddu, Bachisio, additional, Poos, Alexandra M., additional, Derkach, Andriy, additional, Maclachlan, Kylee, additional, Durante, Michael, additional, Diamond, Benjamin, additional, Papadimitriou, Marios, additional, Davies, Faith, additional, Boyle, Eileen M., additional, Walker, Brian, additional, Hultcrantz, Malin, additional, Silva, Ariosto, additional, Hampton, Oliver, additional, Teer, Jamie K., additional, Siegel, Erin M., additional, Bolli, Niccolò, additional, Jackson, Graham H., additional, Kaiser, Martin, additional, Pawlyn, Charlotte, additional, Cook, Gordon, additional, Kazandjian, Dickran, additional, Stein, Caleb, additional, Chesi, Marta, additional, Bergsagel, Leif, additional, Mai, Elias K., additional, Goldschmidt, Hartmut, additional, Weisel, Katja C., additional, Fenk, Roland, additional, Raab, Marc S., additional, Van Rhee, Fritz, additional, Usmani, Saad, additional, Shain, Kenneth H., additional, Weinhold, Niels, additional, Morgan, Gareth, additional, and Landgren, Ola, additional

Published
2024
Full Text
View/download PDF

18. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Author

Mai, Elias K., primary, Hielscher, Thomas, additional, Bertsch, Uta, additional, Salwender, Hans J., additional, Zweegman, Sonja, additional, Raab, Marc S., additional, Munder, Markus, additional, Pantani, Lucia, additional, Mancuso, Katia, additional, Brossart, Peter, additional, Beksac, Meral, additional, Blau, Igor W., additional, Dürig, Jan, additional, Besemer, Britta, additional, Fenk, Roland, additional, Reimer, Peter, additional, van der Holt, Bronno, additional, Hänel, Mathias, additional, von Metzler, Ivana, additional, Graeven, Ullrich, additional, Müller-Tidow, Carsten, additional, Boccadoro, Mario, additional, Scheid, Christof, additional, Dimopoulos, Meletios A., additional, Hillengass, Jens, additional, Weisel, Katja C., additional, Cavo, Michele, additional, Sonneveld, Pieter, additional, and Goldschmidt, Hartmut, additional

Published
2023
Full Text
View/download PDF

19. Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Author

Blaney, Patrick, primary, Walker, Brian A., additional, Mikulasova, Aneta, additional, Gagler, Dylan, additional, Ziccheddu, Bachisio, additional, Diamond, Benjamin, additional, Wang, Yubao, additional, Hou, Liming, additional, Liu, Sanxiong, additional, Poos, Alexandra Maria, additional, Cirrincione, Anthony, additional, Maclachlan, Kylee H, additional, Mai, Elias K., additional, Goldschmidt, Hartmut, additional, Usmani, Saad Z, additional, Raab, Marc S., additional, Weinhold, Niels, additional, Landgren, Ola, additional, Davies, Faith E., additional, Maura, Francesco, additional, and Morgan, Gareth J., additional

Published
2023
Full Text
View/download PDF

20. CD8+CD28−regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Author

Kriegsmann, Katharina, Ton, Gigi Nu Hoang Quy, Awwad, Mohamed H. S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Munder, Markus, Dürig, Jan, Blau, Igor W., Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja C., Salwender, Hans J., Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., and Hundemer, Michael

Published
2024
Full Text
View/download PDF

21. Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)

Author

Boquoi, Amelie, primary, Giagounidis, Aristoteles, additional, Goldschmidt, Hartmut, additional, Heinsch, Michael, additional, Rummel, Mathias J., additional, Kröger, Nicolaus, additional, Mai, Elias K., additional, Strapatsas, Judith, additional, Haas, Rainer, additional, and Kobbe, Guido, additional

Published
2023
Full Text
View/download PDF

22. Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and Radiomics

Author

Wennmann, Markus, primary, Ming, Wenlong, additional, Bauer, Fabian, additional, Chmelik, Jiri, additional, Klein, André, additional, Uhlenbrock, Charlotte, additional, Grözinger, Martin, additional, Kahl, Kim-Celine, additional, Nonnenmacher, Tobias, additional, Debic, Manuel, additional, Hielscher, Thomas, additional, Thierjung, Heidi, additional, Rotkopf, Lukas T., additional, Stanczyk, Nikolas, additional, Sauer, Sandra, additional, Jauch, Anna, additional, Götz, Michael, additional, Kurz, Felix T., additional, Schlamp, Kai, additional, Horger, Marius, additional, Afat, Saif, additional, Besemer, Britta, additional, Hoffmann, Martin, additional, Hoffend, Johannes, additional, Kraemer, Doris, additional, Graeven, Ullrich, additional, Ringelstein, Adrian, additional, Bonekamp, David, additional, Kleesiek, Jens, additional, Floca, Ralf O., additional, Hillengass, Jens, additional, Mai, Elias K., additional, Weinhold, Niels, additional, Weber, Tim F., additional, Goldschmidt, Hartmut, additional, Schlemmer, Heinz-Peter, additional, Maier-Hein, Klaus, additional, Delorme, Stefan, additional, and Neher, Peter, additional

Published
2023
Full Text
View/download PDF

23. Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma

Author

Termini, Rosalinda, Zihala, David, Terpos, Evangelos, Perez-Montana, Albert, Jelinek, Tomas, Raab, Marc, Weinhold, Niels, Mai, Elias K, Grab, Anna Luise, Corre, Jill, Vergez, Francois, Sacco, Antonio, Chiarini, Marco, Giustini, Viviana, Tucci, Alessandra, Rodriguez, Sara, Moreno, Cristina, Perez, Cristina, Maia, Catarina, Martin-Sanchez, Esperanza, Guerrero, Camila, Botta, Cirino, Garces, Juan-Jose, Lopez, Aitziber, Tamariz-Amador, Luis-Esteban, Prosper, Felipe, Bargay, Joan, Cabezudo, Maria-Elena, Ocio, Enrique M, Hajek, Roman, Martinez-Lopez, Joaquin, Solano, Fernando, Iglesias, Rebeca, Paiva, Artur, Geraldes, Catarina, Matos Silva, Helena, Gomez, Clara, De Arriba, Felipe, Ludwig, Heinz, Garcia-Guinon, Antoni, Casanova, Maria, Alegre, Adrian, Cabanas, Valentin, Sirvent, Maialen, Oriol, Albert, de la Rubia, Javier, Hernandez-Rivas, Jose-Angel, Palomera, Luis, Sarasa, Maria, Rios, Pablo, Puig, Noemi, Mateos, Maria-Victoria, Flores-Montero, Juan, Orfao, Alberto, Goldschmidt, Hartmut, Avet-Loiseau, Herve, Roccaro, Aldo M, San-Miguel, Jesus F, Paiva, Bruno, Termini, Rosalinda, Zihala, David, Terpos, Evangelo, Pérez-Montaña, Albert, Jelinek, Toma, Raab, Marc, Weinhold, Niel, Mai, Elias K, Grab, Anna Luise, Corre, Jill, Vergez, Francoi, Sacco, Antonio, Chiarini, Marco, Giustini, Viviana, Tucci, Alessandra, Rodríguez, Sara, Moreno, Cristina, Perez, Cristina, Maia, Catarina, Martin-Sanchez, Esperanza, Guerrero, Camila, Botta, Cirino, Garcés, Juan-Jose, Lopez, Aitziber, Tamariz-Amador, Luis-Esteban, Prósper, Felipe, Bargay, Joan, Cabezudo, Maria-Elena, Ocio, Enrique M, Hájek, Roman, Martinez-Lopez, Joaquin, Solano, Fernando, Iglesias, Rebeca, Paiva, Artur, Geraldes, Catarina, Matos Silva, Helena, Gomez, Clara, De Arriba, Felipe, Ludwig, Heinz, Garcia-Guiñon, Antoni, Casanova, Maria, Alegre, Adrian, Cabañas, Valentin, Sirvent, Maialen, Oriol, Albert, De la Rubia, Javier, Hernández-Rivas, José-Ángel, Palomera, Lui, Sarasa, Maria, Rios, Pablo, Puig, Noemi, Mateos, Maria-Victoria, Flores-Montero, Juan, Orfao, Alberto, Goldschmidt, Hartmut, Avet-Loiseau, Herve, Roccaro, Aldo M, San-Miguel, Jesus F, and Paiva, Bruno

Subjects
Smoldering Multiple Myeloma, Cancer Research, myeloma, Oncology, Disease Progression, Humans, Immunoglobulin Light Chains, Prognosis, Multiple Myeloma, Risk Assessment, circulating tumor cell, immune profile
Abstract

Purpose: Early intervention in smoldering multiple myeloma (SMM) requires optimal risk stratification to avoid under- and overtreatment. We hypothesized that replacing bone marrow (BM) plasma cells (PC) for circulating tumor cells (CTC), and adding immune biomarkers in peripheral blood (PB) for the identification of patients at risk of progression due to lost immune surveillance, could improve the International Myeloma Working Group 20/2/20 model. Experimental Design: We report the outcomes of 150 patients with SMM enrolled in the iMMunocell study, in which serial assessment of tumor and immune cells in PB was performed every 6 months for a period of 3 years since enrollment. Results: Patients with >0.015% versus ≤0.015% CTCs at baseline had a median time-to-progression of 17 months versus not reached (HR, 4.9; P 20% BM PCs had no prognostic value in a multivariate analysis that included serum free light-chain ratio >20, >2 g/dL M-protein, and >0.015% CTCs. The 20/2/20 and 20/2/0.015 models yielded similar risk stratification (C-index of 0.76 and 0.78). The combination of the 20/2/0.015 model with an immune risk score based on the percentages of SLAN+ and SLAN− nonclassical monocytes, CD69+HLADR+ cytotoxic NK cells, and CD4+CXCR3+ stem central memory T cells, allowed patient’ stratification into low, intermediate-low, intermediate-high, and high-risk disease with 0%, 20%, 39%, and 73% rates of progression at 2 years. Conclusions: This study showed that CTCs outperform BM PCs for assessing tumor burden. Additional analysis in larger series are needed to define a consensus cutoff of CTCs for minimally invasive stratification of SMM.

Published
2022

24. Comparison of IGLV2 ‐14 light chain sequences of patients with AL amyloidosis or multiple myeloma

Author

Berghaus, Natalie, primary, Schreiner, Sarah, additional, Poos, Alexandra M., additional, Raab, Marc S., additional, Goldschmidt, Hartmut, additional, Mai, Elias K., additional, Salwender, Hans‐Jürgen, additional, Bernhard, Helga, additional, Thurner, Lorenz, additional, Müller‐Tidow, Carsten, additional, Weinhold, Niels, additional, Hegenbart, Ute, additional, Schönland, Stefan O., additional, and Huhn, Stefanie, additional

Published
2023
Full Text
View/download PDF

25. Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma

Author

John, Lukas, primary, Miah, Kaya, additional, Benner, Axel, additional, Mai, Elias K., additional, Kriegsmann, Katharina, additional, Hundemer, Michael, additional, Kaudewitz, Dorothee, additional, Müller-Tidow, Carsten, additional, Jordan, Karin, additional, Goldschmidt, Hartmut, additional, Raab, Marc S., additional, and Giesen, Nicola, additional

Published
2023
Full Text
View/download PDF

26. Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Author

Termini, Rosalinda, primary, Žihala, David, primary, Terpos, Evangelos, primary, Perez-Montaña, Albert, primary, Jelínek, Tomáš, primary, Raab, Marc, primary, Weinhold, Niels, primary, Mai, Elias K., primary, Grab, Anna Luise, primary, Corre, Jill, primary, Vergez, Francois, primary, Sacco, Antonio, primary, Chiarini, Marco, primary, Giustini, Viviana, primary, Tucci, Alessandra, primary, Rodriguez, Sara, primary, Moreno, Cristina, primary, Perez, Cristina, primary, Maia, Catarina, primary, Martín-Sánchez, Esperanza, primary, Guerrero, Camilla, primary, Botta, Cirino, primary, Garces, Juan-Jose, primary, Lopez, Aitziber, primary, Tamariz-Amador, Luis-Esteban, primary, Prosper, Felipe, primary, Bargay, Joan, primary, Cabezudo, Maria-Elena, primary, Ocio, Enrique M., primary, Hájek, Roman, primary, Martinez-Lopez, Joaquin, primary, Solano, Fernando, primary, Iglesias, Rebeca, primary, Paiva, Artur, primary, Geraldes, Catarina, primary, Vitoria, Helena, primary, Gomez, Clara, primary, De Arriba, Felipe, primary, Ludwig, Heinz, primary, Garcia-Guiñon, Antoni, primary, Casanova, Maria, primary, Alegre, Adrian, primary, Cabañas, Valentin, primary, Sirvent, Maialen, primary, Oriol, Albert, primary, de la Rubia, Javier, primary, Hernández-Rivas, José-Ángel, primary, Palomera, Luis, primary, Sarasa, Maria, primary, Rios, Pablo, primary, Puig, Noemi, primary, Mateos, Maria-Victoria, primary, Flores-Montero, Juan, primary, Orfao, Alberto, primary, Goldschmidt, Hartmut, primary, Avet-Loiseau, Hervé, primary, Roccaro, Aldo M., primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Author

Termini, Rosalinda, primary, Žihala, David, primary, Terpos, Evangelos, primary, Perez-Montaña, Albert, primary, Jelínek, Tomáš, primary, Raab, Marc, primary, Weinhold, Niels, primary, Mai, Elias K., primary, Grab, Anna Luise, primary, Corre, Jill, primary, Vergez, Francois, primary, Sacco, Antonio, primary, Chiarini, Marco, primary, Giustini, Viviana, primary, Tucci, Alessandra, primary, Rodriguez, Sara, primary, Moreno, Cristina, primary, Perez, Cristina, primary, Maia, Catarina, primary, Martín-Sánchez, Esperanza, primary, Guerrero, Camilla, primary, Botta, Cirino, primary, Garces, Juan-Jose, primary, Lopez, Aitziber, primary, Tamariz-Amador, Luis-Esteban, primary, Prosper, Felipe, primary, Bargay, Joan, primary, Cabezudo, Maria-Elena, primary, Ocio, Enrique M., primary, Hájek, Roman, primary, Martinez-Lopez, Joaquin, primary, Solano, Fernando, primary, Iglesias, Rebeca, primary, Paiva, Artur, primary, Geraldes, Catarina, primary, Vitoria, Helena, primary, Gomez, Clara, primary, De Arriba, Felipe, primary, Ludwig, Heinz, primary, Garcia-Guiñon, Antoni, primary, Casanova, Maria, primary, Alegre, Adrian, primary, Cabañas, Valentin, primary, Sirvent, Maialen, primary, Oriol, Albert, primary, de la Rubia, Javier, primary, Hernández-Rivas, José-Ángel, primary, Palomera, Luis, primary, Sarasa, Maria, primary, Rios, Pablo, primary, Puig, Noemi, primary, Mateos, Maria-Victoria, primary, Flores-Montero, Juan, primary, Orfao, Alberto, primary, Goldschmidt, Hartmut, primary, Avet-Loiseau, Hervé, primary, Roccaro, Aldo M., primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Author

Termini, Rosalinda, primary, Žihala, David, primary, Terpos, Evangelos, primary, Perez-Montaña, Albert, primary, Jelínek, Tomáš, primary, Raab, Marc, primary, Weinhold, Niels, primary, Mai, Elias K., primary, Grab, Anna Luise, primary, Corre, Jill, primary, Vergez, Francois, primary, Sacco, Antonio, primary, Chiarini, Marco, primary, Giustini, Viviana, primary, Tucci, Alessandra, primary, Rodriguez, Sara, primary, Moreno, Cristina, primary, Perez, Cristina, primary, Maia, Catarina, primary, Martín-Sánchez, Esperanza, primary, Guerrero, Camilla, primary, Botta, Cirino, primary, Garces, Juan-Jose, primary, Lopez, Aitziber, primary, Tamariz-Amador, Luis-Esteban, primary, Prosper, Felipe, primary, Bargay, Joan, primary, Cabezudo, Maria-Elena, primary, Ocio, Enrique M., primary, Hájek, Roman, primary, Martinez-Lopez, Joaquin, primary, Solano, Fernando, primary, Iglesias, Rebeca, primary, Paiva, Artur, primary, Geraldes, Catarina, primary, Vitoria, Helena, primary, Gomez, Clara, primary, De Arriba, Felipe, primary, Ludwig, Heinz, primary, Garcia-Guiñon, Antoni, primary, Casanova, Maria, primary, Alegre, Adrian, primary, Cabañas, Valentin, primary, Sirvent, Maialen, primary, Oriol, Albert, primary, de la Rubia, Javier, primary, Hernández-Rivas, José-Ángel, primary, Palomera, Luis, primary, Sarasa, Maria, primary, Rios, Pablo, primary, Puig, Noemi, primary, Mateos, Maria-Victoria, primary, Flores-Montero, Juan, primary, Orfao, Alberto, primary, Goldschmidt, Hartmut, primary, Avet-Loiseau, Hervé, primary, Roccaro, Aldo M., primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

29. Supplement 5 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

30. Supplement 6 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

31. Supplement 1 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

32. Supplement 2 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

33. Supplement 7 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

34. Supplement 3 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

35. Supplement 8 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

36. Supplement 4 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Author

Fenk, Roland, primary, Giagounidis, Aristoteles, primary, Goldschmidt, Hartmut, primary, Heinsch, Michael, primary, Rummel, Mathias, primary, Kroger, Nicolaus, primary, Boquoi, Amelie, primary, Lopez, David, primary, Gerrlich, Celina, primary, Baier, Julia, primary, Liesenjohann, Svenja, primary, Hauck, Katarzyna, primary, Savickaite, Ingrida, primary, Mai, Elias K., primary, Aul, Carlo, primary, Strapatsas, Judith, primary, Dienst, Ariane, primary, Kondakci, Mustafa, primary, Haas, Rainer, primary, and Kobbe, Guido, primary

Published
2023
Full Text
View/download PDF

37. Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

Author

Kriegsmann, Katharina, primary, Manta, Calin, additional, Schwab, Ricarda, additional, Mai, Elias K., additional, Raab, Marc S., additional, Salwender, Hans J., additional, Fenk, Roland, additional, Besemer, Britta, additional, Dürig, Jan, additional, Schroers, Roland, additional, von Metzler, Ivana, additional, Hänel, Mathias, additional, Mann, Christoph, additional, Asemissen, Anne M., additional, Heilmeier, Bernhard, additional, Bertsch, Uta, additional, Huhn, Stefanie, additional, Müller-Tidow, Carsten, additional, Goldschmidt, Hartmut, additional, and Hundemer, Michael, additional

Published
2023
Full Text
View/download PDF

38. Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients

Author

Kaiser, Martin F., primary, Sonneveld, Pieter, additional, Cairns, David, additional, Raab, Marc S, additional, Larocca, Alessandra, additional, Brown, Sarah R, additional, Baertsch, Marc-A., additional, Li, Cong, additional, Musto, Pellegrino, additional, Yong, Kwee, additional, Mai, Elias K, additional, Capra, Andrea, additional, Cook, Gordon, additional, Goldschmidt, Hartmut, additional, Boccadoro, Mario, additional, Jackson, Graham, additional, Weinhold, Niels, additional, and Gay, Francesca, additional

Published
2022
Full Text
View/download PDF

39. Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome

Author

Steiger, Simon, primary, Lutz, Raphael, additional, Prokoph, Nina, additional, Palit, Subarna, additional, Tirier, Stephan M, additional, Reichert, Philipp, additional, Baumann, Anja, additional, Hefner, Nadine, additional, Schumacher, Sabrina, additional, Vonficht, Dominik, additional, Grünschläger, Florian, additional, Poos, Alexandra M, additional, John, Lukas, additional, Haghverdi, Laleh, additional, Mallm, Jan-Philipp, additional, Mai, Elias K, additional, Friedrich, Mirco, additional, Kriegsmann, Katharina, additional, Awwad, Mohamed H.S., additional, Jauch, Anna, additional, Bertsch, Uta, additional, Tichy, Diana, additional, Müller-Tidow, Carsten, additional, Schroers, Roland, additional, Salwender, Hans, additional, Besemer, Britta, additional, Fenk, Roland, additional, Weisel, Katja, additional, Goldschmidt, Hartmut, additional, Huhn, Stefanie, additional, Hundemer, Michael, additional, Rippe, Karsten, additional, Haas, Simon, additional, Weinhold, Niels, additional, and Raab, Marc S, additional

Published
2022
Full Text
View/download PDF

40. Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma

Author

Mai, Elias K, primary, Huhn, Stefanie, additional, Miah, Kaya, additional, Poos, Alexandra M, additional, Scheid, Christof, additional, Weisel, Katja, additional, Bertsch, Uta, additional, Munder, Markus, additional, Berlanga, Oscar, additional, Hose, Dirk, additional, Seckinger, Anja, additional, Jauch, Anna, additional, Blau, Igor Wolfgang, additional, Haenel, Mathias, additional, Salwender, Hans, additional, Benner, Axel, additional, Raab, Marc S, additional, Goldschmidt, Hartmut, additional, and Weinhold, Niels, additional

Published
2022
Full Text
View/download PDF

41. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Author

Goldschmidt, Hartmut, primary, Mai, Elias K, additional, Bertsch, Uta, additional, Fenk, Roland, additional, Nievergall, Eva, additional, Tichy, Diana, additional, Besemer, Britta, additional, Dürig, Jan, additional, Schroers, Roland, additional, von Metzler, Ivana, additional, Hänel, Mathias, additional, Mann, Christoph, additional, Asemissen, Anne M, additional, Heilmeier, Bernhard, additional, Weinhold, Niels, additional, Huhn, Stefanie, additional, Kriegsmann, Katharina, additional, Luntz, Steffen P, additional, Holderried, Tobias A W, additional, Trautmann-Grill, Karolin, additional, Gezer, Deniz, additional, Klaiber-Hakimi, Maika, additional, Müller, Martin, additional, Khandanpour, Cyrus, additional, Knauf, Wolfgang, additional, Scheid, Christof, additional, Munder, Markus, additional, Geer, Thomas, additional, Riesenberg, Hendrik, additional, Thomalla, Jörg, additional, Hoffmann, Martin, additional, Raab, Marc S, additional, Salwender, Hans J, additional, Weisel, Katja C, additional, Behringer, Joachim, additional, Bernhard, Helga, additional, Bernhardt, Christiane, additional, Blau, Igor W, additional, Bolling, Claus, additional, Debatin, Daniel, additional, Dingeldein, Gerrit, additional, Ferstl, Barbara, additional, Fest, Claudia, additional, Fronhoffs, Stefan, additional, Fuhrmann, Stephan, additional, Gaska, Tobias, additional, Goldschmidt, Hartmut, additional, Görner, Martin, additional, Graeven, Ullrich, additional, Grassinger, Jochen, additional, Heinsch, Michael, additional, Held, Gerhard, additional, Hopfer, Olaf, additional, Immenschuh, Peter, additional, Kaddu-Mulindwa, Dominic, additional, Klausmann, Martine, additional, Klein, Stefan, additional, Ko, Yon-Dschun, additional, Köchling, Georg, additional, Koenigsmann, Michael, additional, Kostrewa, Philippe, additional, Kraemer, Doris Maria, additional, Kremers, Stephan, additional, Kropff, Martin, additional, La Rosée, Paul, additional, Mahlberg, Rolf, additional, Martens, Uwe, additional, Neise, Michael, additional, Nückel, Holger, additional, Pönisch, Wolfram, additional, Procaccianti, Maria, additional, Rafiyan, Mohammed R, additional, Reimer, Peter, additional, Riecke, Armin, additional, Rummel, Mathias, additional, Runde, Volker, additional, Schaich, Markus, additional, Scheid, Christoph, additional, Schmidt-Hieber, Martin, additional, Schmitt, Stefan, additional, Schöndube, Daniel, additional, Schwarzer, Andreas, additional, Staib, Peter, additional, Steiniger, Heike, additional, Sturmberg, Dirk, additional, Tischler, Hans-Joachim, additional, Trummer, Arne, additional, Tschechne, Barbara, additional, Verbeek, Walter, additional, Whitlock, Bettina, additional, de Wit, Maike, additional, Zaiß, Matthias, additional, and Ziske, Carsten, additional

Published
2022
Full Text
View/download PDF

42. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Author

D'Agostino, Mattia, primary, Cairns, David A., additional, Lahuerta, Juan José, additional, Wester, Ruth, additional, Bertsch, Uta, additional, Waage, Anders, additional, Zamagni, Elena, additional, Mateos, María-Victoria, additional, Dall'Olio, Daniele, additional, van de Donk, Niels W.C.J., additional, Jackson, Graham, additional, Rocchi, Serena, additional, Salwender, Hans, additional, Bladé Creixenti, Joan, additional, van der Holt, Bronno, additional, Castellani, Gastone, additional, Bonello, Francesca, additional, Capra, Andrea, additional, Mai, Elias K., additional, Dürig, Jan, additional, Gay, Francesca, additional, Zweegman, Sonja, additional, Cavo, Michele, additional, Kaiser, Martin F., additional, Goldschmidt, Hartmut, additional, Hernández Rivas, Jesús María, additional, Larocca, Alessandra, additional, Cook, Gordon, additional, San-Miguel, Jesús F., additional, Boccadoro, Mario, additional, and Sonneveld, Pieter, additional

Published
2022
Full Text
View/download PDF

43. Comprehensive genomic characterization of refractory multiple myeloma reveals a complex mutational and structural landscape associated with drug resistance [Abstract]

Author

Lehners, Nicola, Toprak, Umut H., Xu, Jing, Paramasivam, Nagarajan, Hübschmann, Daniel, Fröhlich, Martina, Hanafiah, Nur H. Md., Mughal, Sadaf, Mai, Elias K., Jauch, Anna, Hillengass, Jens, Eils, Roland, Müller-Tidow, Carsten, Brors, Benedikt, Goldschmidt, Hartmut, Schlesner, Matthias, and Raab, Marc S.

Subjects
ddc:610
Published
2022

45. Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma

Author

Mai, Elias K., Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M., Scheid, Christof, Weisel, Katja, Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor Wolfgang, Haenel, Mathias, Salwender, Hans, Benner, Axel, Raab, Marc S., Goldschmidt, Hartmut, Weinhold, Niels, Mai, Elias K., Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M., Scheid, Christof, Weisel, Katja, Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor Wolfgang, Haenel, Mathias, Salwender, Hans, Benner, Axel, Raab, Marc S., Goldschmidt, Hartmut, and Weinhold, Niels

Published
2022

46. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma:A European Myeloma Network (EMN) Report Within the HARMONY Project

Author

D'agostino, Mattia, Cairns, David A., Lahuerta, Juan José, Wester, Ruth, Bertsch, Uta, Waage, Anders, Zamagni, Elena, Mateos, María Victoria, Dall'olio, Daniele, Van De Donk, Niels W.C.J., Jackson, Graham, Rocchi, Serena, Salwender, Hans, Bladé Creixenti, Joan, Van Der Holt, Bronno, Castellani, Gastone, Bonello, Francesca, Capra, Andrea, Mai, Elias K., Dürig, Jan, Gay, Francesca, Zweegman, Sonja, Cavo, Michele, Kaiser, Martin F., Goldschmidt, Hartmut, Hernández Rivas, Jesús María, Larocca, Alessandra, Cook, Gordon, San-Miguel, Jesús F., Boccadoro, Mario, Sonneveld, Pieter, D'agostino, Mattia, Cairns, David A., Lahuerta, Juan José, Wester, Ruth, Bertsch, Uta, Waage, Anders, Zamagni, Elena, Mateos, María Victoria, Dall'olio, Daniele, Van De Donk, Niels W.C.J., Jackson, Graham, Rocchi, Serena, Salwender, Hans, Bladé Creixenti, Joan, Van Der Holt, Bronno, Castellani, Gastone, Bonello, Francesca, Capra, Andrea, Mai, Elias K., Dürig, Jan, Gay, Francesca, Zweegman, Sonja, Cavo, Michele, Kaiser, Martin F., Goldschmidt, Hartmut, Hernández Rivas, Jesús María, Larocca, Alessandra, Cook, Gordon, San-Miguel, Jesús F., Boccadoro, Mario, and Sonneveld, Pieter

Abstract

PURPOSEPatients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. Moreover, chromosome 1q gain/amplification (1q+) recently proved to be a poor prognostic factor. In this study, we revised the R-ISS by analyzing the additive value of each single risk feature, including 1q+.PATIENTS AND METHODSThe European Myeloma Network, within the HARMONY project, collected individual data from 10,843 patients with NDMM enrolled in 16 clinical trials. An additive scoring system on the basis of top features predicting progression-free survival (PFS) and overall survival (OS) was developed and validated.RESULTSIn the training set (N = 7,072), at a median follow-up of 75 months, ISS, del(17p), lactate dehydrogenase, t(4;14), and 1q+ had the highest impact on PFS and OS. These variables were all simultaneously present in 2,226 patients. A value was assigned to each risk feature according to their OS impact (ISS-III 1.5, ISS-II 1, del(17p) 1, high lactate dehydrogenase 1, and 1q+ 0.5 points). Patients were stratified into four risk groups according to the total additive score: low (Second Revision of the International Staging System [R2-ISS]-I, 19.2%, 0 points), low-intermediate (II, 30.8%, 0.5-1 points), intermediate-high (III, 41.2%, 1.5-2.5 points), high (IV, 8.8%, 3-5 points). Median OS was not reached versus 109.2 versus 68.5 versus 37.9 months, and median PFS was 68 versus 45.5 versus 30.2 versus 19.9 months, respectively. The score was validated in an independent validation set (N = 3,771, of whom 1,214 were with complete data to calculate R2-ISS) maintaining its prognostic value.CONCLUSIONThe R2-ISS is a simple prognostic staging system allowing a better stratification of patients with intermediate-risk NDMM. The additive nature of this score fosters its future implementation with new pro

Published
2022

47. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities

Author

Giesen, Nicola, primary, Paramasivam, Nagarajan, additional, Toprak, Umut H., additional, Huebschmann, Daniel, additional, Xu, Jing, additional, Uhrig, Sebastian, additional, Samur, Mehmet, additional, Bähr, Stella, additional, Fröhlich, Martina, additional, Mughal, Sadaf S., additional, Mai, Elias K., additional, Jauch, Anna, additional, Müller-Tidow, Carsten, additional, Brors, Benedikt, additional, Munshi, Nikhil, additional, Goldschmidt, Hartmut, additional, Weinhold, Niels, additional, Schlesner, Matthias, additional, and Raab, Marc S., additional

Published
2022
Full Text
View/download PDF

48. Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

Author

Goldschmidt, Hartmut, primary, Mai, Elias K, additional, Nievergall, Eva, additional, Fenk, Roland, additional, Bertsch, Uta, additional, Tichy, Diana, additional, Besemer, Britta, additional, Dürig, Jan, additional, Schroers, Roland, additional, Metzler, Ivana v., additional, Haenel, Mathias, additional, Mann, Christoph, additional, Asemissen, Anne-Marie, additional, Heilmeier, Bernhard, additional, Huhn, Stefanie, additional, Kriegsmann, Katharina, additional, Weinhold, Niels, additional, Luntz, Steffen P., additional, Holderried, Tobias A. W., additional, Trautmann-Grill, Karolin, additional, Gezer, Deniz, additional, Klaiber-Hakimi, Maika, additional, Mueller, Martin, additional, Khandanpour, Cyrus, additional, Knauf, Wolfgang, additional, Munder, Markus, additional, Geer, Thomas, additional, Riesenberg, Hendrik, additional, Thomalla, Joerg, additional, Hoffmann, Martin, additional, Raab, Marc-Steffen, additional, Salwender, Hans, additional, and Weisel, Katja, additional

Published
2021
Full Text
View/download PDF

49. Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

Author

Mai, Elias K, primary, Hielscher, Thomas, additional, Bertsch, Uta, additional, Salwender, Hans, additional, Zweegman, Sonja, additional, Munder, Markus, additional, Pantani, Lucia, additional, Brossart, Peter, additional, Beksac, Meral, additional, Blau, Igor Wolfgang, additional, Raab, Marc-Steffen, additional, Dürig, Jan, additional, Giesen, Nicola, additional, Besemer, Britta, additional, Fenk, Roland, additional, Reimer, Peter, additional, van der Holt, Bronno, additional, Haenel, Mathias, additional, Metzler, Ivana v., additional, Graeven, Ullrich, additional, Boccadoro, Mario, additional, Scheid, Christof, additional, Dimopoulos, Meletios A., additional, Weisel, Katja, additional, Cavo, Michele, additional, Sonneveld, Pieter, additional, and Goldschmidt, Hartmut, additional

Published
2021
Full Text
View/download PDF

50. Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Author

Goldschmidt, Hartmut, primary, Mai, Elias K, additional, Bertsch, Uta, additional, Besemer, Britta, additional, Haenel, Mathias, additional, Miah, Kaya, additional, Fenk, Roland, additional, Schlenzka, Jana, additional, Munder, Markus, additional, Dürig, Jan, additional, Blau, Igor Wolfgang, additional, Huhn, Stefanie, additional, Hose, Dirk, additional, Jauch, Anna, additional, Kunz, Christina, additional, Neubauer, Andreas, additional, Scheid, Christof, additional, Schroers, Roland, additional, Metzler, Ivana v., additional, Schieferdecker, Aneta, additional, Thomalla, Joerg, additional, Reimer, Peter, additional, Mahlberg, Rolf, additional, Graeven, Ullrich, additional, Kremers, Stephan, additional, Martens, Uwe M., additional, Kunz, Christian, additional, Hensel, Manfred, additional, Seidel-Glaetzer, Andrea, additional, Weisel, Katja, additional, Raab, Marc-Steffen, additional, and Salwender, Hans, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results